Arcutis Biotherapeutics, Inc.·4

Nov 21, 6:21 PM ET

Gilbert Halley E 4

4 · Arcutis Biotherapeutics, Inc. · Filed Nov 21, 2025

Insider Transaction Report

Form 4
Period: 2025-11-20
Transactions
  • Sale

    Common Stock

    2025-11-20$27.55/sh16,532$455,44222,123 total
  • Exercise/Conversion

    Stock Option (right to buy)

    2025-11-2012,2200 total
    Exercise: $7.51Exp: 2033-05-31Common Stock (12,220 underlying)
  • Exercise/Conversion

    Common Stock

    2025-11-20$7.51/sh+12,220$91,77238,655 total
Footnotes (2)
  • [F1]The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of May 31, 2023, subject to the non-employee director's continuous service.
  • [F2]The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $27.32 to $27.72, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Documents

1 file
  • 4
    wk-form4_1763767283.xmlPrimary

    FORM 4